Israeli Gastroenterology SIBO Diagnosis Guidelines 2026

Introduction

A new national consensus guideline from the Israeli Gastroenterology Association provides the most specific standards to date for diagnosing SIBO and related disorders. Published in 2026, this expert-led document directly addresses widespread inconsistencies in how hydrogen-methane breath tests are performed and interpreted, offering a clear path for more accurate diagnosis and targeted treatment for patients with persistent gut symptoms.

How New Standards Clarify a Murky Diagnostic Process

For years, diagnosing SIBO has been controversial. Different clinics used varied protocols for breath tests, leading to inconsistent diagnoses and patient confusion. The Israeli multidisciplinary panel, led by researchers from Tel Aviv Sourasky University Medical Center and Rabin Medical Center, held eight meetings to resolve this. Their core recommendation is the simultaneous measurement of hydrogen and methane in every test. This is critical because methane-producing archaea consume hydrogen. A patient can have significant gut overgrowth that only produces methane, yielding a negative hydrogen reading. Without dual measurement, these cases are missed.

The guideline also solidifies lactulose as the preferred test substrate over glucose. While both are sugars fermented by gut bacteria, lactulose is not absorbed by the human small intestine, allowing it to travel further and potentially detect overgrowth deeper in the gut. Glucose is absorbed early, which may limit its detection range. However, the panel acknowledges glucose remains a valid alternative, particularly when rapid absorption is desirable. This standardization aims to harmonize data globally so research and treatment outcomes can be more reliably compared.

Methane Gets Its Own Diagnosis and Symptoms Gain New Importance

A major shift in the 2026 guideline is the formal recognition of intestinal methanogen overgrowth (IMO) as a distinct condition. While often grouped under the SIBO umbrella, IMO involves archaea, not bacteria. These organisms produce methane, a gas strongly associated with constipation-predominant symptoms. The panel’s work validates that treating a “methane-positive” gut requires a different approach than a “hydrogen-positive” one, impacting antibiotic and dietary choices.

Furthermore, the panel insists that symptom recording during the breath test is not optional. Patients must log symptoms like bloating, pain, and diarrhea in real-time. This practice directly informs treatment by differentiating carbohydrate malabsorption (a positive breath test with symptoms) from carbohydrate intolerance (a positive test without symptoms). Someone may ferment a sugar perfectly well but experience no distress, making aggressive treatment unnecessary. This symptom-driven interpretation moves patient management beyond a simple positive/negative result toward personalized care.

From Diagnosis to Treatment: Implementing the New Consensus

These research-backed standards have immediate practical applications. For patients seeking a SIBO or IMO test, they can now ask clinics if they follow the 2026 consensus guidelines, specifically whether they measure both gases and use lactulose. A proper test requires strict patient preparation: a special diet the day before, a 12-hour fast, and avoiding antibiotics, probiotics, and laxatives for weeks prior. Results must be interpreted by a specialist who understands how conditions like prior bowel surgery or slow transit—common in IBS-C and pelvic floor disorders—can affect the timing of gas readings.

For clinicians, the guideline supports a more rational treatment sequence. A positive hydrogen-dominant SIBO test may lead to a specific antibiotic like rifaximin. A positive methane-dominant IMO test often requires a combination therapy, such as rifaximin with neomycin. The clear link between methane and constipation also supports integrating these findings with broader IBS-C treatment strategies. Following treatment, a standardized repeat breath test can objectively measure success, moving away from reliance on symptoms alone.

Frequently Asked Questions

What’s the difference between SIBO and IMO?

SIBO (small intestinal bacterial overgrowth) involves an excess of hydrogen-producing bacteria, while IMO (intestinal methanogen overgrowth) involves methane-producing archaea, single-celled organisms distinct from bacteria. IMO is strongly linked to constipation.

Why is measuring both hydrogen and methane so important?

Methane-producing archaea consume hydrogen gas. If a test measures only hydrogen, a patient with significant IMO could appear negative, leading to a false diagnosis and lack of treatment.

How should I prepare for a SIBO breath test?

Preparation is strict: follow a specific low-fermentation diet the day before, fast for 12 hours, and avoid antibiotics, probiotics, and laxatives for several weeks as directed by your doctor to ensure an accurate result.

If my breath test is positive but I have no symptoms during it, do I have SIBO?

According to the new guidelines, this likely indicates carbohydrate malabsorption without intolerance. Treatment may not be necessary unless you experience daily symptoms, highlighting why real-time symptom tracking during the test is essential.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42434160/
https://pubmed.ncbi.nlm.nih.gov/42402885/
https://pubmed.ncbi.nlm.nih.gov/42378001/